Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 1 1

Status

Terminated 2Completed 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Other solid neoplasm 1Other hematologic neoplasm 1Gastrointestinal 1

Conditions

Pancreatic Neoplasms 1Hematologic Neoplasms 1Advanced Solid Tumor 1

Interventions

pembrolizumab 1033Carboplatin 971Paclitaxel 942Gemcitabine 799Cisplatin 757Docetaxel 698Bevacizumab 637Nivolumab 520Pemetrexed 507Capecitabine 475Cyclophosphamide 473Fluorouracil 425Dexamethasone 410Rituximab 391Oxaliplatin 352Injections 347Trastuzumab 314atezolizumab 312Cetuximab 291Leucovorin 290Irinotecan 271130-nm albumin-bound paclitaxel 257Prednisone 251Ipilimumab 244Doxorubicin 241Lenalidomide 231Fulvestrant 226fludarabine 219durvalumab 211Erlotinib Hydrochloride 196

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × APG-1387 × Clear all
NCT04284488 2026-01-08

Dose-escalation Study of APG-1387 and Toripalimab in Solid Tumors

Ascentage Pharma Group Inc.

Phase 1/2 Terminated
40 enrolled
Other solid neoplasm

Advanced Solid Tumor

NCT04643405 2026-01-08

APG-1387 Plus Chemotherapy in Advanced Pancreatic Adenocarcinoma

Ascentage Pharma Group Inc.

Phase 1/2 Terminated
21 enrolled
Gastrointestinal

Pancreatic Neoplasms

NCT03386526 2023-02-01

APG-1387 in Patients With Advanced Solid Tumors or Hematologic Malignancies

Ascentage Pharma Group Inc.

Phase 1 Completed
90 enrolled
Other hematologic neoplasm

Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡